GlassScriptPhysician profile
Mohammad Bilal Awan
NPI 1235665647
$1,881.85
in general payments reported to CMS, 2019-2025
22 companies · $966 in 2025
The $966 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2024: $816 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.90 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $347.67 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $275.80 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $180.82 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $125.34 | 2024-2025 | Nuzyra |
| Exact Sciences Corporation | $115.58 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $114.62 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Abbvie INC. | $96.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $84.58 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.84 | 2024-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $65.15 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.52 | 2025 | Jardiance |
| Abbott Laboratories | $41.72 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $40.85 | 2024 | |
| Boston Scientific Corporation | $29.22 | 2025 | Watchman Flx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $25.70 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $24.79 | 2024 | Gemtesa |
| Amphastar Pharmaceuticals, INC. | $23.40 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $23.26 | 2025 | |
| Astellas Pharma US INC | $19.82 | 2024 | Veozah |
| Insulet Corporation | $18.01 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $13.16 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.